Pfizer reported plummeting demand for its Covid vaccines and treatments, with an overall revenue decline of over 40% compared to last year, and a $2.4 billion loss that included a $5.6 billion charge for Covid inventory write-offs.
Pfizer now thinks 2023 revenue from shots and pills for the disease will total about $12.5 billion, over a 75% decrease from last year.
Peers trade at around 5 times sales, and if Pfizer did too its enterprise value would be about $235 billion.
Instead it’s almost 20% less, and the stock is worth one-fifth less than it was at the end of 2019.
They do not reflect the views of Reuters News, which, under the Trust Principles, is committed to integrity, independence, and freedom from bias.
Persons:
Ivan Alvarado, It’s, Peers, it’s, What’s, Robert Cyran, John Foley, Aditya Sriwatsav
Organizations:
Pfizer, REUTERS, Reuters, Covid, X, Vodafone, Thomson
Locations:
Santiago , Chile, Spain